Compare Quest Diagnostics Inc (DGX) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Roundhill Magnificent Seven ETF — how do they compare? Quest Diagnostics Inc trades at $230.94 (market cap $25.48B), while Roundhill Magnificent Seven ETF trades at $73.79 (market cap $5.78B). The key difference: Quest Diagnostics Inc is far larger — about 4.4× Roundhill Magnificent Seven ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| DGX | MAGS | |
|---|---|---|
Market Cap | $25.48B | $5.78B |
Volume | 941,866 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $73.90 |
52-Week Low | $173.49 | $55.39 |
Typical Hold Time | 56 Days | 36 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.63, down slightly by 0.08% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights ongoing investor debate about the Magnificent Seven's leadership role amid shifting AI investment trends.
The ETF faces near-term pressure from underperformance versus the S&P 500 but maintains long-term growth potential through diversified tech exposure. Key risks include concentration in seven stocks and market rotation away from mega-caps, while the bullish technical setup suggests potential for near-term recovery if AI momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
